|
| | 
|
 | |
         
|  |
|  |
|
Mostrar Noticias: Ver noticias de otros activosBúsqueda de noticias relacionadas a la acción Biogen Idec Inc. (ordenadas por fecha):
|
The biggest R&D spenders in biotechFierceBiotechAs Biogen Idec ($BIIB) showed over the past year, unhappy investors will back off on calls to cut research costs if you show some major headway on big new products. Now I'm waiting to see if the new crew in charge of Amgen ($AMGN) will win a grace ...y más » |
|
Midday Glance: Biotechnology companiesCBS NewsNEW YORK ? Shares of some top biotechnology companies are down at 1 pm: Amgen Inc. fell $.84 or 1.2 percent, to $68.07. Biogen Idec fell $.57 or .4 percent, to $131.76. Celgene Corp. fell $.91 or 1.3 percent, to $68.74. Gilead Sciences Inc. fell $.61 ...y más » |
|
Data on Elan & Biogen's TysabriZacks.comBiogen Idec (BIIB - Analyst Report) and Elan Corporation, plc (ELN - Snapshot Report) recently announced the publishing of research from the Tysabri risk management program in the New England Journal of Medicine. The research was based on data from ...y más » |
|
Data on Elan & Biogen's Tysabri - Analyst BlogNASDAQBiogen Idec ( BIIB ) and Elan Corporation, plc ( ELN ) recently announced the publishing of research from the Tysabri risk management program in the New England Journal of Medicine . The research was based on data from Tysabri trials, post-marketing ...y más » |
|
Zacks Reaffirms Neutral Rating on Biogen Idec (BIIB)Daily PoliticalBiogen Idec (NASDAQ: BIIB)'s stock had its ?neutral? rating restated by Zacks in a report issued on Wednesday. They currently have a $138.00 target price on the stock. Zacks' analyst wrote, ?Biogen's first quarter earnings per share of $1.39 were below ...y más » |
|
Three new rules for biopharma collaborationsFierceBiotechTake Biogen Idec's ($BIIB) recent buyout of Stromedix for its Phase II-ready antibody STX-100 for combating fibrosis. Apparently, Pfizer ($PFE) was interested in buying the asset, Jose-Carlos Gutierrez-Ramos, senior vice president of biotherapeutics ... |
|
Standard Review for Biogen's BG-12Zacks.comBiogen Idec (BIIB - Analyst Report) recently announced the acceptance of its regulatory filings in the US and EU for its oral multiple sclerosis candidate, BG-12. The US Food and Drug Administration (FDA) has granted standard review to the candidate, ...y más » |
|
FDA Concludes Safety Review Of Novartis MS Drug GilenyaWall Street Journal(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The US Food and Drug Administration Monday ...y más » |
|
Notable ETF Outflow Detected - QQEW, WCRX, STX, BIIBForbesAmong the largest underlying components of QQEW, in trading today Warner Chilcott Plc (NASD: WCRX) is up about 2.1%, Seagate Technology Plc (NASD: STX) is up about 0.9%, and Biogen Idec Inc (NASD: BIIB) is higher by about 0.5%. |
|
Biogen and Comcast Among 52-Week High Leaders TuesdayWall St. Cheat SheetBy Derek Hoffman Biogen Idec Inc (NASDAQ:BIIB): Based upon data available to us through the TOUCH prescribing program and other third-party sources, as of the end of March 2012, we estimate that approximately 66600 patients were on commercial and ...y más » |
|
Santé Canada approuve la mise à jour de la monographie de TYSABRI ...CNW Telbec (Communiqué de presse)TORONTO, le 23 mai 2012 /CNW/ - Biogen Idec vient d'annoncer que Santé Canada a approuvé les modifications apportées à la monographie de TYSABRI® qui aideront à mieux peser les risques et avantages chez les divers patients atteints de la sclérose en ... |
|
FDA Concludes Safety Review Of Novartis MS Drug GilenyaFox BusinessThe FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a ...y más » |
|
Anchura de la Página:
Imagen de Fondo: |
|  | |
|
|
